Terran Biosciences, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F

Concert Pharmaceuticals, Inc. placed all of its hope on a deuterated formulation of ruxolitinib in alopecia areata, offloading other programs to bet on deuruxolitinib that it would offer a better saf